What is CellCentric?
CellCentric operates at the vanguard of precision medicine, specializing in the development of innovative small-molecule drugs designed to target specific cancer pathways. By leveraging deep scientific expertise, the company focuses on translating complex biological insights into viable therapeutic interventions. Its market position is defined by a commitment to rigorous clinical validation and a strategic approach to drug discovery that prioritizes efficacy and patient outcomes in oncology. As a key player in the United Kingdom's biotech ecosystem, CellCentric maintains a focus on high-impact research that bridges the gap between laboratory discovery and clinical application.
How much funding has CellCentric raised?
CellCentric has raised a total of $424M across 5 funding rounds:
Unspecified
$26M
Unspecified
$33M
Other Financing Round
$25M
Series C
$120M
Series D
$220M
Unspecified (2018): $26M with participation from Morningside Venture Partners
Unspecified (2020): $33M led by Morningside Venture Investments
Other Financing Round (2023): $25M supported by Pfizer
Series C (2025): $120M featuring BrightEdge, Avego Healthcare Capital, Forbion, and RA Capital Management
Series D (2026): $220M backed by Sofinnova Partners, Avego, HBM Partners, Fidelity, RA Capital Management, Forbion, Pfizer, BrightEdge - American Cancer Society, and Venrock
Key Investors in CellCentric
Sofinnova Partners
A leading European venture capital firm in life sciences, specializing in healthcare and sustainability with a hands-on approach to company building.
HBM Partners
A Swiss healthcare investment firm managing significant assets, focusing on venture, growth, and buy-out financings in the biopharma and medtech sectors.
Pfizer
A global biopharmaceutical leader that researches, develops, and manufactures medicines and vaccines across multiple therapeutic areas, including oncology.
What's next for CellCentric?
With the recent capital injection, CellCentric is well-positioned to scale its clinical development programs and strengthen its operational infrastructure. The strategic focus will likely shift toward advancing its lead candidates through late-stage clinical trials, while simultaneously exploring potential partnerships to enhance its commercialization strategy. Given the participation of top-tier life sciences investors, the company is expected to maintain its trajectory of scientific excellence, potentially setting the stage for future regulatory milestones or strategic exits. The firm remains dedicated to its core mission of transforming cancer care through evidence-based innovation and sustainable growth.
See full CellCentric company page
